THAT — Thalia Therapeutics Share Price
0.000.00%
Last trade - 00:00- £3.75m
- £2.02m
- £0.01m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.12 | ||
| Price to Tang. Book | 2.12 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 529.74 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -67.98% | ||
| Return on Equity | -70.64% | ||
| Operating Margin | -16991.09% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | £m | n/a | n/a | n/a | 0 | 0.01 | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Thalia Therapeutics PLC, formerly N4 Pharma plc, is a biotechnology company developing RNA-based therapeutics and delivery technologies in oncology and cardiovascular disease. The Company is developing proprietary RNA delivery technologies (Nuvec) designed to enable multi-RNA loading, flexible targeting and the potential for oral delivery. Nuvec is based on amorphous silica and has an irregular surface structure that simply and effectively traps and protects RNA as it travels to target cells. The Nuvec delivery system can be functionalized by attaching a wide range of proteins, peptides, antibodies or radionuclides for therapeutic purposes. The Company has a growing pipeline of RNA-based programs across oncology and cardiovascular disease, including Dual-target cardiovascular siRNA program and Proprietary RNA delivery technology. The Company is advancing a novel long-duration, dual-acting siRNA program targeting PCSK9 and lipoprotein.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- June 30th, 2025
- Incorporated
- July 6th, 1979
- Public Since
- June 7th, 2005
- No. of Employees
- 4
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- London Stock Exchange
- Shares in Issue
- 832,280,349
- Address
- C/O ARCH LAW HUCKLETREE BISHOPSGATE, LONDON, EC2N 4BQ
- Web
- https://investors.thaliatx.com
- Phone
- +44 1332690061
- Auditors
- Gravita II LLP
Upcoming Events for THAT
Half Year 2026 N4 Pharma PLC Earnings Release
Similar to THAT
4Basebio
London Stock Exchange
Arecor Therapeutics
London Stock Exchange
Avacta
London Stock Exchange
Batm Advanced Communications
London Stock Exchange
Bioventix
London Stock Exchange
FAQ
What is the Thalia Therapeutics share price?
As of Today at 23:40 UTC, shares in Thalia Therapeutics are trading at 0.45p. This share price information is delayed by 15 minutes.
How has the Thalia Therapeutics share price performed this year?
Shares in Thalia Therapeutics last closed at 0.45p and the price had moved by +20% over the past 365 days. In terms of relative price strength the Thalia Therapeutics share price has underperformed the FTSE All Share Index by -8.82% over the past year.
What are the analyst and broker recommendations for Thalia Therapeutics?
There is no consensus recommendation for this security.
Find out moreWhat is the Thalia Therapeutics dividend yield?
Thalia Therapeutics does not currently pay a dividend.
Does Thalia Therapeutics pay a dividend?
Thalia Therapeutics does not currently pay a dividend.
When does Thalia Therapeutics next pay dividends?
Thalia Therapeutics does not currently pay a dividend.
How do I buy Thalia Therapeutics shares?
To buy shares in Thalia Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Thalia Therapeutics?
As of the previous close price of 0.45p, shares in Thalia Therapeutics had a market capitalisation of £3.75m.
Where are Thalia Therapeutics shares listed?
Here are the trading details for Thalia Therapeutics:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: THAT
What kind of share is Thalia Therapeutics?
Based on an overall assessment of its quality, value and momentum Thalia Therapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Thalia Therapeutics share price forecast for 2026?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the Thalia Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Thalia Therapeutics. Over the past six months, its share price has underperformed the FTSE All Share Index by -32.38%.
As of the last closing price of 0.45p, shares in Thalia Therapeutics were trading -11.82% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Thalia Therapeutics PE Ratio?
The Thalia Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at 0.45p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Thalia Therapeutics?
Thalia Therapeutics' management team is headed by:
- John Chiplin - NEC
- Nigel Theobald - CEO
- Luke Cairns - EDR
- David Templeton - EDR
- Christopher Britten - NED